




The relative strengths and weaknesses of Oncternal Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncternal Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Oncternal Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 324%, being 104% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	56,815
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,495
Liabilities, Non-Current	0
Other Assets	452
Other Compr. Net Income	0
Other Expenses	-8,821
Other Liabilities	0
Other Net Income	13,836
Other Revenues	0
Property and Equipment	507
Research and Development	38,887
Selling, General and Administrative Expense	10,845

Output Variable	Value in 1000 USD
Assets	57,774
Liabilities	9,495
Expenses	40,911
Revenues	0
Stockholders Equity	48,279
Net Income	-27,075
Comprehensive Net Income	-27,075
BaseVar	61,008
ECR before LimitedLiability	232%
Economic Capital Ratio	324%